Newsroom

Picture of Chase Beisel
News
The gene scissors CRISPR-Cas are an important tool for genome editing. However, their functionality is limited because they rely on specific sequences to operate. Their ancient ancestors, on the other hand, may have been much more versatile. Rediscovering their forgotten abilities and harnessing them for biotechnological applications is the goal of the “RGNcestry” research project led by Chase Beisel, affiliated department head at the Helmholtz Institute for RNA-based Infection Research (HIRI). The European Research Council (ERC) is funding the project with ten million euros over a period of six years.
23.12.2025
Digitale Darstellung mehrere Menschen
News
Rare diseases affecting fewer than five in 10,000 people are often particularly difficult to diagnose and treat. As part of their joint funding program “zukunft.niedersachsen”, the state of Lower Saxony and the Volkswagen Foundation have now selected nine promising research projects for funding that aim to develop new diagnoses and treatments for rare diseases. Among them are two projects from the Helmholtz Centre for Infection Research (HZI). The PREDICT-CTP consortium of TWINCORE, the HZI, and Hannover Medical School (MHH) is developing a new diagnostic method for rheumatic diseases. In the StopPSC project, researchers from the HZI and MHH are developing new agents to treat primary sclerosing cholangitis, a chronically progressive inflammation of the bile ducts.
22.12.2025
EHEC bacteria on an intestinal cell
News
Experts are increasingly turning to machine learning to predict antibiotic resistance in pathogens. With its help, resistance mechanisms can be identified based on a pathogen’s genetics. However, the results should be viewed with caution: Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg have shown that the models are often less reliable than assumed. Their findings were published in the journal PLOS Biology. They contribute to the development of more reliable tools for predicting and combating antibiotic resistance.
17.12.2025
Teaser for the podcast with Andreas Keller
News
At first glance, biology and computer science seem like opposites. But wherever enormous amounts of data are generated from research, progress is hardly possible without digital methods. Bioinformatician Prof. Andreas Keller therefore relies on artificial intelligence. He heads the department “Clinical Bioinformatics” at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). In this episode of InFact, he talks about how AI can help us understand how beneficial and harmful bacteria communicate with each other in our bodies, how to predict when infections will cause long-term effects, and how this can be used to develop new drugs against dangerous pathogens.
16.12.2025
Elisabeth Strunk in the lab
News
Biphenomycins, natural products derived from bacteria, show excellent antimicrobial activity, but have long remained out of reach for drug development. The main obstacle was the limited understanding of how these compounds are produced by their microbial hosts. A research team led by Tobias Gulder, department head at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), has now deciphered the biosynthetic pathway of the biphenomycins, establishing the foundation for their pharmaceutical advancement. The team published its findings in the journal Angewandte Chemie International Edition.
11.12.2025
Maximilian Order awarded to HIRI Director Jörg Vogel by Marcus Söder
News
On December 3, Jörg Vogel, Director of the Helmholtz Institute for RNA-based Infection Research, was honored with the Maximilian Order for Science and Art at a ceremony held in the Antiquarium of the Munich Residence. He received the distinction from Bavarian Minister-President Markus Söder, who referred to the Free State’s highest honor as the ‘Bavarian Nobel Prize’. HIRI is site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität Würzburg (JMU).
04.12.2025

HZI in the media

... fünf Teams durch, darunter PROTON vom Helmholtz-Zentrum für Infektionsforschung. Dieses entwickelt einen neuartigen Wirkstoff gegen ...

22.03.2026
|
Ad Hoc News

Vor allem durch die Coronapandemie sind Forschende des Helmholtz-Zentrums für Infektionsforschung in den vergangenen Jahren bundesweit bekannt geworden. Auf welche Themen die Einrichtung für die Zukunft setzt.

20.03.2026
|
Deutsches Ärzteblatt

... beschäftigt sich daneben unter dem Dach des Helmholtz Institutes für Pharmazeu­tische Forschung Saarland (HIPS) ...

18.03.2026
|
Biermann Medizin

... Ausbau von Produktions- und Vermarktungskapazitäten.

 

Das Helmholtz-Zentrum für Infektionsforschung HZI begrüßt den Erhalt der GMP- ...

18.03.2026
|
Bionity.COM

... der Universität zu Lübeck, des Helmholtz-Zentrums für Infektionsforschung (HZI) in Braunschweig, der Medizinischen Hochschule Hannover ...

17.03.2026
|
Biermann Medizin

Vorsorge Das Coronavirus hält die Welt nicht mehr in Atem. Doch was, wenn ein ­anderer gefährlicher Erreger auftaucht? So wappnet sich unser Gesundheitssystem

16.03.2026
|
Apotheken Umschau

... stumpfen ab“, erklärt Marc Brönstrup vom Helmholtz-Zentrum für Infektionsforschung in Braunschweig. Neue Antibiotika sind dringend ...

14.03.2026
|
ARD Mediathek

... der Medizinischen Hochschule Hannover und dem Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig neue Wirkstoffe ...

13.03.2026
|
MTA Dialog

... späten 1990ern hob sie der am Saarbrücker Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) tätige ...

08.03.2026
|
Saarbrücker Zeitung

European institutions, including Germany’s Helmholtz Institute for RNA-based Infection Research, Helmholtz Center for Infection Research,

06.03.2026
|
Clinical Lab Products

Die Zellen kontrollieren die Reaktion des Immunsystems und verhindern Schäden durch Selbstangriffe. Forschende arbeiten daran, sie zur Therapie einzusetzen.

05.03.2026
|
NDR Norddeutscher Rundfunk

Nachwuchsgruppe „Nanoinfektionsbiologie“ am HZI. Diese Lücke soll das Projekt ONEMUC (Respiratorischer Mukus als One Health-Schnittstelle) ...

03.03.2026
|
DeutschesGesundheitsPortal

Register now for the HZI-Newsletter